
New guidelines from the US Food and Drug Administration (FDA) concerning the development of cancer treatments could have a big impact on the sector, says Genmab’s CEO Jan van de Winkel.
At the end of January, the FDA launched a new project, Optimus, which will require companies developing cancer drugs to do more work to find the optimal dose, so that the best effect can be achieved with the lowest possible dosage.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app